Harbour BioMed Announces Positive Profit Alert
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 4, 2023 /PRNewswire/ -- Harbour BioMed (HKEX: 02142) announced that the first patient has been dosed in its ongoing phase I trial of the first-in-class anti-B7H7 (HHLA2) antibody HBM1020 (NCT05824663/Study 1020.1) in the United States. This study is evaluating the safety, tolerability, pharmacokinetics, and anti-tumor activity of HBM1020 in patients with advanced solid tumors.